Home
/
BioNexus Gene Lab Corp
/
Financials
/
Quarterly
BioNexus Gene Lab Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BioNexus Gene Lab Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$2.54M
Nov 14, 2025
Q2
2025
Jun 30, 2025
$2.26M
Aug 18, 2025
Q1
2025
Mar 31, 2025
$2.14M
May 15, 2025
Q3
2025
Sep 30, 2024
$2.63M
Nov 14, 2025
Q2
2025
Jun 30, 2024
$1.97M
Aug 18, 2025
Q1
2025
Mar 31, 2024
$2.38M
May 15, 2025
Q3
2024
Sep 30, 2023
$2.55M
Nov 15, 2024
Q2
2024
Jun 30, 2023
$2.57M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$2.38M
May 15, 2024
Q3
2023
Sep 30, 2022
$2.58M
Mar 26, 2024
Q2
2023
Jun 30, 2022
$2.49M
Aug 16, 2023
Q1
2023
Mar 31, 2022
$3.03M
May 9, 2023
Q3
2022
Sep 30, 2021
$3.58M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$3.09M
Aug 15, 2022
Q1
2022
Mar 31, 2021
$3.45M
May 16, 2022
Q3
2021
Sep 30, 2020
$3.09M
Nov 15, 2021
Q2
2021
Jun 30, 2020
$1.10M
Aug 12, 2021
Q1
2021
Mar 31, 2020
$3.07M
May 18, 2021
Q3
2020
Sep 30, 2019
$24.2K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$21.6K
Aug 11, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($709.0K)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($616.2K)
Aug 18, 2025
Q1
2025
Mar 31, 2025
($623.3K)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.35M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
$199.1K
Aug 18, 2025
Q3
2024
Jun 30, 2024
$199.1K
Nov 15, 2024
Q1
2025
Mar 31, 2024
($103.8K)
May 15, 2025
Q3
2024
Mar 31, 2024
($103.8K)
Nov 15, 2024
Q2
2024
Mar 31, 2024
($103.8K)
Aug 14, 2024
Q3
2024
Sep 30, 2023
($2.61M)
Nov 15, 2024
Q3
2024
Jun 30, 2023
($259.3K)
Nov 15, 2024
Q2
2024
Jun 30, 2023
($259.3K)
Aug 14, 2024
Q3
2024
Mar 31, 2023
($69.1K)
Nov 15, 2024
Q1
2024
Mar 31, 2023
($69.1K)
May 15, 2024
Q2
2024
Mar 31, 2023
($69.1K)
Aug 14, 2024
Q3
2023
Sep 30, 2022
($77.4K)
Mar 26, 2024
Q3
2023
Jun 30, 2022
($138.7K)
Mar 26, 2024
Q2
2023
Jun 30, 2022
($138.7K)
Aug 16, 2023
Q2
2023
Mar 31, 2022
$17.1K
Aug 16, 2023
Q1
2023
Mar 31, 2022
$17.1K
May 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($702.5K)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($611.3K)
Aug 18, 2025
Q1
2025
Mar 31, 2025
($618.4K)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.34M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
$259.2K
Aug 18, 2025
Q1
2025
Mar 31, 2024
($79.0K)
May 15, 2025
Q3
2024
Sep 30, 2023
($2.53M)
Nov 15, 2024
Q2
2024
Jun 30, 2023
($272.2K)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($50.6K)
May 15, 2024
Q3
2023
Sep 30, 2022
($65.2K)
Mar 26, 2024
Q2
2023
Jun 30, 2022
($138.0K)
Aug 16, 2023
Q1
2023
Mar 31, 2022
$34.7K
May 9, 2023
Q3
2022
Sep 30, 2021
$372.6K
Nov 14, 2022
Q2
2022
Jun 30, 2021
$140.0K
Aug 15, 2022
Q1
2022
Mar 31, 2021
$342.1K
May 16, 2022
Q3
2021
Sep 30, 2020
$237.3K
Nov 15, 2021
Q2
2021
Jun 30, 2020
($34.0K)
Aug 12, 2021
Q1
2021
Mar 31, 2020
$1.07M
May 18, 2021
Q3
2020
Sep 30, 2019
($50.1K)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($69.2K)
Aug 11, 2020